Compound heterozygosity for two novel missense mutations in the prothrombin gene in a patient with a severe bleeding tendency

Thrombosis and Haemostasis

Volumn 77, Issue 4, 1997, Pages 610-615

  Poort, S R ^a   Landolfi, R ^b   Bertina, R M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTHROMBIN;

ADULT; ARTICLE; BLEEDING TENDENCY; CASE REPORT; CONTROLLED STUDY; DNA POLYMORPHISM; FATHER; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; HYPOPROTHROMBINEMIA; INFANT; MALE; MISSENSE MUTATION; MOTHER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGENY;

EID: 0030891620     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656020     Document Type: Article

References (46)

1. Jackson CM. Physiology and biochemistry of prothrombin. In: Haemostasis and Thrombosis, vol 1. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds). Edinburgh: Churchill Livingstone (3th ed) 1994: 397-438.
2. Degen SJF, MacGillivray RTA, Davie EW. Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. Biochem 1983; 22: 2087-97.
3. Degen SJF, Davie EW. Nucleotide sequence of the gene for human prothrombin. Biochem 1987; 26: 6165-77.
4. Royle NJ, Irwin DM, Koschinsky ML, MacGillivray RTA, Hamerton JL. Human genes encoding prothrombin and ceruloplasmin map to 11p11-q12 and 3q21-24, respectively. Somat Cell Mol Genet 1987; 13: 285-92.
5. Tuddenham EGD, Cooper DN. Prothrombin. In: The molecular genetics of haemostasis and its inherited disorders. Motulsky AG, Bobrow M, Harper PS, Scriver C (eds). Oxford, New York, Tokyo: Oxford University Press 1994: 136-48.
6. Board PG, Shaw DC. Determination of the amino acid substitution in human prothrombin type 3 (157 glu-to-lys) and the localization of a third thrombin cleavage site. Brit J Haematol 1983; 54: 245-54.
7. Rabiet MJ, Furie BC, Furie B. Molecular defect of prothrombin Barcelona. Substitution of cysteine for arginine at residue 273. J Biol Chem 1986; 261: 15045-8.
8. Rabiet MJ, Furie BC, Furie B. Molecular defect of prothrombin Madrid. Substitution of arginine 273 by cysteine precludes activation. Thromb Haemost 1987; 58: 313 (abstract).
9. Miyata T, Monta T, Inomoto T, Kawauchi A, Shirakami A, Iwanaga S. Prothrombin Tokushima, a replacement of arginine-418 by tryptophan that impairs the fibrinogen clotting activity of derived thrombin Tokushima. Biochem 1987; 26: 1117-22.
10. Hedner U, Davie EW. Introduction to hemostasis and the vitamin K-dependent coagulation factors. In: The metabolic basis of inherited disease, Vol II. Scriver CR, Beaudet AL, Sly WS, Valle D (eds). New York: McGraw-Hill (6th ed) 1989: 2107-34.
11. Henriksen RA, Mann KG. Identification of the primary structural defect in the dysthrombin thrombin Quick-I. Substitution of cysteine for arginine-382. Biochem 1988; 27: 9160-5.
12. Henriksen RA, Mann KG. Substitution of valine for glycin-558 in the congenital dysthrombin Quick-II alters primary substrate specificity. Biochem 1989; 28: 2078-82.
13. Morishita E, Saito M, Kumabushiri I, Asakura H, Matsuda T, Yamaguchi K. Prothrombin Himi: a compound heterozygote for two dysfunctional prothrombin molecules (Met-337 → Thr and Arg-388 → His). Blood 1992; 80: 2275-80.
14. Miyata T, Aruga R, Umeyama H, Bezeaud A, Guillin MC, Iwanaga S. Prothrombin Salakta. Substitution of glumatic acid -466 by alanine reduces the fibrinogen clotting activity and the esterase activity. Biochem 1992; 31: 7457-62.
15. Degen SJF, McDowell SA, Sparks LM, Scharrer I. Prothrombin Frankfurt: a dysfunctional prothrombin characterized by substitution of glu-466 by ala. Thromb Haemost 1995; 73: 203-9.
16. Tamary H, Surray S, Augustine JG, Schwartz E, Rappaport EF. Molecular characterization of hypoprothrombinemia. Blood 1991; 78: 65a.
17. Iwahana H, Yoshimoto K, Shigekiyo T, Shirakami A, Saito S, Itakura M. Molecular and genetic analysis of a compound heterozygote for dysprothrombinemia of prothrombin Tokushima and hypoprothrombinemia. Am J Hum Genet 1992; 51: 1386-95.
18. Poort SR, Michiels JJ, Reitsma PH, Bertina RM. Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder. Thromb Haemost 1994; 72: 819-24.
19. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning. A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1982.
20. Saiki RK, Gelfland DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-91.
21. Sanger F, Nicklen S, Coulsen AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7.
22. MacGillivray RTA, Irwin DM, Guinto ER, Stone JC. Recombinant genetic approaches to functional mapping of thrombin. Ann NY Acad Sci USA 1986; 485: 73-9.
23. Jorgensen MJ, Cantor AB, Furie BC, Furie B. Expression, isolation and characterization of biologically active γ-carboxylated recombinant human prothrombin. Circulation 1986; 74 (suppl. II): Abstr. 1637.
24. Walz DA, Hewett-Emmett D, Seegers WH. Amino acid sequence of human prothrombin fragments 1 and 2. Proc Natl Acad Sci USA 1977; 74: 1969-72.
25. Iwahana H, Yoshimoto K, Itakura M. Highly polymorphic region of the human prothrombin (F2) gene. Hum Genet 1992; 89: 123-4.
26. Iwahana H, Yoshimoto K, Itakura M. NcoI RFLP in the human prothrombin (F2) gene. Nucl Acids Res 1991; 19: 4309.
27. Magnesson S, Sottrup-Jensen L, Petersen TE, Claeys H. The primary structure of prothrombin, the role of vitamin K in blood coagulation and a thrombin-catalyzed "negative feedback" control mechanism for limiting the activation of prothrombin. In: Prothrombin and related coagulation factors. Hemker HC, Veltkamp JJ (eds). Leiden University Press 1975; 25.
28. Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 1985; 41: 657-63.
29. Gardell SJ, Duong LT, Diehl RE, York JD, Hare TR, Register RB, Jacobs JW, Dixon RAF, Friedman PA. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989; 264: 17947-52.
30. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-7.
31. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-3.
32. Han SH, Stuart A, Degen SJF. Characterization of the DNF15S2 locus on human chromosome 3: identification of a gene coding for four kringle domains with homology to hepatocyte growth factor. Biochem 1991; 30: 9768-80.
33. Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y, Kitamura N. Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. J Biol Chem 1993; 268: 10024-8.
34. Jennings CGB, Dyer SM, Burden SJ. Muscle-specific trk-related receptor with a kringle domain defines a distinct class of receptor tyrosine kinases. Proc Natl Acad Sci USA 1993; 90: 2895-9.
35. Wilson C, Goberdhan DCI, Steller H. Dror, a potential neurotrophic receptor gene, encodes a Drosophila homolog of the vertebrate Ror family of trk-related receptor tyrosine kinases. Proc Natl Acad Sci USA 1993; 90: 7109-13.
36. Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res 1993; 69: 1-58.
37. Tulinsky A, Park CH, Mao B, Llinas M. Lysine/fibrin binding sites of kringle modeled after the structure of kringle 1 of prothrombin. Proteins 1988; 3: 85-96.
38. Tulinsky A. The structure of domains of blood proteins. Thromb Haemost 1991; 66: 16-31.
39. Hamaguchi N, Charifson P, Darden T, Xiao L, Padmanabhan K, Tulinsky A, Hiskey R, Pedersen L. Molecular dynamics simulation of bovine prothrombin fragment 1 in the presence of calcium ions. Biochem 1992; 31: 8840-8.
40. Giannelli F, Green PM, High KA, Sommer S, Poon MC, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Brownlee GG. Haemophilia B: a database of point mutations and short additions and deletions -fourth edition. Nucl Acid Res 1993; 21: 3075-87.
41. Green PM, Montandon AJ, Bently DR, Giannelli F. Genetics and molecular biology of haemophilia A and B. Blood Coag Fibrinol 1991; 2: 539-65.
42. Reitsma PH, Bernardi F, Doig RG, Gandrille S, Greengard JS, Ireland H, Krawczak M, Lind B, Long GL, Poort SR, Saito H, Sala N, Witt I, Cooper DN. Protein C deficiency: a database of mutations, 1995 update. Thromb Haemost 1995; 73: 876-89.
43. Bar-Shavit R, Kahn AJ, Mann KG, Wilner GD. Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci USA 1986; 83: 976-80.
44. Loeliger EA, Lewis SM. Progress in laboratory control of oral anticoagulants. Lancet 1982; 2: 318-20.
45. Loeliger EA, van den Besselaar AMHP, Lewis SM. Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thromb Haemost 1985; 53: 148-54.
46. Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983; 49: 238-44.